The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy.
A number of antibody products have now become accepted as effective anti-cancer therapies. Despite being mainly designed to act by inhibiting functional tumour antigens, there is increasing evidence that Fc-mediated engagement of the immune system is an important contributor to the efficacy of several of these therapies. The optimisation of this engagement offers the potential not only to augment efficacy against existing targets, but also to exploit non-functional tumour antigens. Antibodies that achieve efficacy wholly or predominantly through Fc-mediated mechanisms, represent rich opportunities for future therapeutics in oncology. This mini review summarises some of the key challenges, which need to be addressed to select the most effective molecules. These include the identification of optimal antibody characteristics and improvement of the drug discovery process, in particular, the relevance and predictive power of existing in vitro and in vivo screening methods. Advances in our understanding of tumour immunobiology and successful application of technologies designed to enhance immune system engagement will further aid this process.
Griggs
J
J
UCB, 216 Bath Road, Slough, Berkshire SL1 4EN, UK. jeremygriggs77@yahoo.co.uk
Zinkewich-Peotti
K
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*
D000911:Antibodies, Monoclonal